TGTX Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.81 |
| 52 Week High | US$29.32 |
| 52 Week Low | US$6.46 |
| Beta | 2.33 |
| 1 Month Change | -7.97% |
| 3 Month Change | -5.78% |
| 1 Year Change | -45.45% |
| 3 Year Change | -58.36% |
| 5 Year Change | 122.05% |
| Change since IPO | 1,291.41% |
Recent News & Updates
TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03Recent updates
TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Shareholder Returns
| TGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.4% | 4.2% | 1.8% |
| 1Y | -45.4% | 8.1% | 22.8% |
Return vs Industry: TGTX underperformed the US Biotechs industry which returned 9% over the past year.
Return vs Market: TGTX underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TGTX has not had significant price volatility in the past 3 months.
Volatility Over Time: TGTX's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 284 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| TGTX fundamental statistics | |
|---|---|
| Market cap | US$2.37b |
| Earnings (TTM) | US$41.20m |
| Revenue (TTM) | US$289.33m |
54.9x
P/E Ratio7.8x
P/S RatioIs TGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TGTX income statement (TTM) | |
|---|---|
| Revenue | US$289.33m |
| Cost of Revenue | US$18.72m |
| Gross Profit | US$270.62m |
| Other Expenses | US$229.42m |
| Earnings | US$41.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 93.53% |
| Net Profit Margin | 14.24% |
| Debt/Equity Ratio | 63.5% |
How did TGTX perform over the long term?
See historical performance and comparison